keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophagic junction cancer

keyword
https://www.readbyqxmd.com/read/28815080/mckeown-or-ivor-lewis-totally-minimally-invasive-esophagectomy-for-cancer-of-the-esophagus-and-gastroesophageal-junction-systematic-review-and-meta-analysis
#1
Frans van Workum, Gijs H Berkelmans, Bastiaan R Klarenbeek, Grard A P Nieuwenhuijzen, Misha D P Luyer, Camiel Rosman
BACKGROUND: Minimally invasive esophagectomy (MIE) has consistently been associated with improved perioperative outcome and similar oncological safety compared to open esophagectomy. However, it is currently unclear what type of MIE is preferred for patients with resectable esophageal cancer. METHODS: Literature was searched in Medline, Embase and the Cochrane library combining relevant search terms. Articles that included patients undergoing totally minimally invasive esophagectomy (TMIE) or hybrid minimally invasive esophagectomy (HMIE) and compared McKeown with Ivor Lewis procedures were included...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28807364/initial-results-of-the-oesophageal-and-gastric-cancer-registry-from-the-comunidad-valenciana
#2
Javier Escrig, Fernando Mingol, Roberto Martí, José Puche, Ramón Trullenque, José Antonio Barreras, Francisco Asencio, Javier Aguiló, José Manuel Navarro, Carmen Alberich, Dolores Salas, Francisco Javier Lacueva
AIMS: To evaluate the initial results of the oesophagogastric cancer registry developed for the Sociedad Valenciana de Cirugía and the Health Department of the Comunidad Valenciana (Spain). MATERIAL AND METHODS: Fourteen of the 24 public hospitals belonging to the Comunidad Valenciana participated. All patients with diagnosis of oesophageal or gastric carcinomas operated from January 2013 to December 2014 were evaluated. Demographic, clinical and pathological data were analysed...
August 11, 2017: Cirugía Española
https://www.readbyqxmd.com/read/28807249/current-trends-in-multimodality-treatment-of-esophageal-and-gastroesophageal-junction-cancer-review-article
#3
REVIEW
Fredrik Klevebro, Simon Ekman, Magnus Nilsson
PURPOSE: Multimodality treatment has now been widely introduced in the curatively intended treatment of esophageal and gastroesophageal junction cancer. We aim to give an overview of the scientific evidence for the available treatment strategies and to describe which trends that are currently developing. METHODS: We conducted a review of the scientific evidence for the different curatively intended treatment strategies that are available today. Relevant articles of randomized controlled trials, cohort studies, and meta analyses were included...
September 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28782986/her2-heterogeneity-in-gastroesophageal-cancer-detected-by-testing-biopsy-and-resection-specimens
#4
Ladan Fazlollahi, Helen E Remotti, Alina Iuga, Hui-Min Yang, Stephen M Lagana, Antonia R Sepulveda
CONTEXT: - In advanced gastric, esophageal, and gastroesophageal junction adenocarcinomas (GE-GEJ-AC) that overexpress ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2), anti-HER2 monoclonal antibody therapy confers survival benefit. To select patients for treatment, HER2 expression and gene amplification are evaluated by immunohistochemistry (IHC) and in situ hybridization. OBJECTIVE: - To determine whether GE-GEJ-AC tested for HER2 on biopsy specimens of a primary tumor show different IHC scores and/or HER2 amplification by in situ hybridization in matched resection specimens, potentially changing therapy eligibility...
August 7, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28767564/post-treatment-pre-operative-pet-response-is-not-an-independent-predictor-of-outcomes-for-patients-with-gastric-and-gej-adenocarcinoma
#5
Jonathan M Hernandez, Volkan Beylergil, Debra A Goldman, Elke van Beek, Mithat Gonen, Laura Tang, Robert Downey, Nabil Rizk, Manish Shah, Vivian Strong, Yelena Janjigian, Heiko Schöder, Daniel G Coit
OBJECTIVE: To determine whether changes in positron emission tomography (PET) avidity correlated with histologic response and were independently associated with outcome. BACKGROUND: The implications of metabolic response to neoadjuvant therapy as measured by repeat PET imaging remain ill-defined for patients with gastric and gastroesophageal junction (GEJ) cancers. METHODS: We identified patients with gastric and GEJ adenocarcinoma who were evaluated with PET imaging before and following neoadjuvant treatment, and subsequently underwent curative resections...
August 1, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28765618/lauren-subtypes-of-advanced-gastric-cancer-influence-survival-and-response-to-chemotherapy-real-world-data-from-the-agamenon-national-cancer-registry
#6
Paula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, Ana Custodio, Juana Maria Cano, Alejandra Lacalle, Isabel Echavarria, Ismael Macias, Monserrat Mangas, Laura Visa, Elvira Buxo, Felipe Álvarez Manceñido, Antonio Viudez, Carles Pericay, Aitor Azkarate, Avinash Ramchandani, Carlos López, Eva Martinez de Castro, Ana Fernández Montes, Federico Longo, Rodrigo Sánchez Bayona, Maria Luisa Limón, Asun Diaz-Serrano, Alfonso Martin Carnicero, David Arias, Paula Cerdà, Fernando Rivera, Jose Maria Vieitez, Manuel Sánchez Cánovas, M Garrido, J Gallego
BACKGROUND: The choice of chemotherapy in HER2-negative gastric cancer is based on centre's preferences and adverse effects profile. No schedule is currently accepted as standard, nor are there any factors to predict response, other than HER2 status. We seek to evaluate whether Lauren type influences the efficacy of various chemotherapies and on patient overall survival (OS). METHODS: We have conducted a multicenter study in 31 hospitals. The eligibility criteria include diagnosis of stomach or gastroesophageal junction adenocarcinoma, HER2 negativity, and chemotherapy containing 2-3 drugs...
August 1, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28736645/effect-of-helicobacter-pylori-infection-on-outcomes-in-resected-gastric-and-gastroesophageal-junction-cancer
#7
Jennifer M Kolb, Umut Ozbek, Noam Harpaz, Randall F Holcombe, Celina Ang
BACKGROUND: Helicobacter pylori (H pylori) infection is a known risk factor for gastric cancer (GC) and has been linked with gastroesophageal junction (GEJ) cancer. Studies examining the relationship between H. pylori infection, GC characteristics and prognosis are limited and have yielded conflicting results. We report on the clinicopathologic characteristics and oncologic outcomes of gastric and GEJ cancer patients with and without a history of H. pylori treated at our institution. METHODS: We retrospectively reviewed the medical records of patients over the age of 18 years who underwent curative resection for GEJ and GC at Mount Sinai Hospital between 2007 and 2012 who had histopathologic documentation of the presence or absence of H pylori infection...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28716815/exposure-response-analyses-of-ramucirumab-from-two-randomized-phase-iii-trials-of-second-line-treatment-for-advanced-gastric-or-gastroesophageal-junction-cancer
#8
Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A Ajani, Jiri Tomasek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S Melemed, Ling Gao, David Ferry, Charles S Fuchs
Ramucirumab is an IgG1 monoclonal antibody specific for the vascular endothelial growth factor receptor-2. Ramucirumab, 8 mg/kg every two weeks, administered as monotherapy (REGARD) or in combination with paclitaxel (RAINBOW), was safe and effective in patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer. We evaluated exposure-efficacy and exposure-safety relationships of ramucirumab from two randomized, placebo-controlled phase III trials. Sparse pharmacokinetic samples were collected and a population pharmacokinetic analysis was conducted to predict ramucirumab minimum trough concentration at steady-state (Cmin,ss)...
July 17, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28712164/efficacy-and-toxicity-of-carboplatin-paclitaxel-based-chemoradiation-for-localized-oesophageal-cancer
#9
Maria Qubtia, Yasir Ishaq, Kiran Munawar, Farhana Badar, Ather Kazmi
BACKGROUND: The management of Oesophageal and Gastroesophageal junction cancers is challenging. Multimodality therapy with carboplatin/paclitaxel based chemoradiation (CRT) and surgery shows improved efficacy. In this study, we wanted to establish the efficacy and safety of CRT for neoadjuvant and radical treatment of localized oesophageal cancer. METHODS: Patients with oesophageal cancer, registered between September 2013 and October 2014 were reviewed retrospectively...
January 2017: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28680718/prognostic-factor-analysis-of-overall-survival-in-gastric-cancer-from-two-phase-iii-studies-of-second-line-ramucirumab-regard-and-rainbow-using-pooled-patient-data
#10
Charles S Fuchs, Kei Muro, Jiri Tomasek, Eric Van Cutsem, Jae Yong Cho, Sang-Cheul Oh, Howard Safran, György Bodoky, Ian Chau, Yasuhiro Shimada, Salah-Eddin Al-Batran, Rodolfo Passalacqua, Atsushi Ohtsu, Michael Emig, David Ferry, Kumari Chandrawansa, Yanzhi Hsu, Andreas Sashegyi, Astra M Liepa, Hansjochen Wilke
PURPOSE: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. MATERIALS AND METHODS: We pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW)...
June 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28671728/clonality-analysis-of-synchronous-gastroesophageal-junction-carcinoma-and-distal-gastric-cancer-by-whole-exome-sequencing
#11
Xiaofang Xing, Shuqin Jia, Jianmin Wu, Qin Feng, Bin Dong, Bo Li, Yongning Jia, Fei Shan, Ying'ai Li, Yan Zhang, Ying Hu, Xiaodong Wang, Xiangtao Liu, Shiwei Yu, Lianhai Zhang, Zhaode Bu, Aiwen Wu, Ziyu Li, Jiafu Ji
Gastroesophageal junction (GEJ) carcinoma and distal gastric cancer (GC) have distinct epidemiology and clinical features and their relationship is uncertain. Synchronous multiple gastric cancers located mostly at proximal and distal sites provide rare specimens for investigating the comprehensive genomic relationships among these cancers in the context of identical genetic circumstances. Formalin-fixed, paraffin-embedded (FFPE) samples from 12 patients with synchronous GEJ carcinoma and distal GC were collected in this study...
July 3, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28667466/safety-pharmacokinetic-and-clinical-activity-profiles-of-ramucirumab-in-combination-with-three-platinum-fluoropyrimidine-doublets-in-japanese-patients-with-chemotherapy-na%C3%A3-ve-metastatic-gastric-gastroesophageal-junction-cancer
#12
Kohei Shitara, Shigenori Kadowaki, Tomohiro Nishina, Daisuke Sakai, Reigetsu Yoshikawa, Yongzhe Piao, Akihiro Ozeki, Koichi Inoue, Ismael Gritli, Kei Muro
BACKGROUND: We evaluated the safety, tolerability, pharmacokinetics, and tumor response of ramucirumab in combination with one of three platinum/fluoropyrimidine regimens in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. METHODS: In this phase 1b study, patients received 8 mg/kg ramucirumab on days 1 and 8 every 3 weeks, following one of three regimens: capecitabine + cisplatin, XP; S-1 + cisplatin, SP; or S-1 + oxaliplatin, SOX...
June 30, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28662341/a-phase-ii-study-of-the-c-met-inhibitor-tivantinib-in-combination-with-folfox-for-the-treatment-of-patients-with-previously-untreated-metastatic-adenocarcinoma-of-the-distal-esophagus-gastroesophageal-junction-or-stomach
#13
Shubham Pant, Manish Patel, Carla Kurkjian, Brian Hemphill, Maria Flores, Dana Thompson, Johanna Bendell
BACKGROUND: This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach. METHODS: Patients with advanced solid tumors for which FOLFOX would be appropriate chemotherapy received escalating doses of tivantinib BID (days 1-14) in a standard 3 + 3 design in phase I...
June 29, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28655793/efficacy-of-sequential-ipilimumab-monotherapy-vs-best-supportive-care-for-unresectable-locally-advanced-metastatic-gastric-or-gastroesophageal-junction-cancer
#14
Yung-Jue Bang, Jae Yong Cho, Yeul Hong Kim, Jin Won Kim, Maria Di Bartolomeo, Jaffer A Ajani, Kensei Yamaguchi, Agnes Balogh, Teresa Sanchez, Markus Moehler
Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase 2 study evaluated the safety and efficacy of ipilimumab monotherapy vs best supportive care among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy.<br /><br />Experimental Design: Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity...
June 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28642830/a-rare-case-of-esophageal-adenocarcinoma-with-urinary-bladder-metastasis
#15
Heather Katz, Rahoma E Saad, Krista Denning, Toni O Pacioles
Metastatic esophageal adenocarcinoma to the urinary bladder is extremely rare. We describe a previously healthy 49-year-old female with recent diagnosis of adenocarcinoma of the gastroesophageal junction with metastatic disease to the liver. Biopsy was positive for human epidermal growth factor receptor 2 (HER2) by Fluorescence In Situ Hybridization (FISH). She received six cycles of Cisplatin, 5-Fluorouracil, and Herceptin and subsequently developed symptomatic anemia and hematuria. Cystoscopy with retroflexion was performed and she received a transurethral resection of bladder tumor with fulguration...
2017: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/28634748/exposure-response-relationship-of-ramucirumab-in-east-asian-patients-from-rainbow-a-randomized-clinical-trial-in-second-line-treatment-of-gastric-cancer
#16
Tae You Kim, Chia-Jui Yen, Salah-Eddin Al-Batran, David Ferry, Ling Gao, Yanzhi Hsu, Rebecca Cheng, Mauro Orlando, Atsushi Ohtsu
BACKGROUND: Ramucirumab is a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor-2. Second-line ramucirumab, in conjunction with paclitaxel (ramucirumab 8 mg/kg or placebo in combination with 80 mg/m(2) paclitaxel), has been shown to be effective and safe in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in RAINBOW, a global phase III randomized clinical trial. We conducted an exploratory exposure-response analysis of efficacy and safety of ramucirumab in East Asian patients from the RAINBOW trial...
June 20, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28614054/survival-benefit-of-anti-angiogenic-agents-in-patients-with-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-a-meta-analysis
#17
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim, Hyun Joo Jang
There is a debate as to whether anti-angiogenic molecular agents can produce survival benefits in patients with previously treated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). We performed this meta-analysis of randomized trials to evaluate the survival outcomes of an anti-angiogenic agent versus placebo in the salvage treatment of advanced GC or GEJC. Electronic databases were searched for eligible studies. From the four studies, 910 patients with previously treated advanced GC or GEJC were included in the meta-analysis...
May 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28591092/the-role-of-radiation-therapy-in-upper-gastrointestinal-cancers
#18
David H Ilson
Upper gastrointestinal cancers are common and account for a high proportion of cases of cancer-related morbidity and mortality. Combined-modality therapy with surgery, chemotherapy, and radiation therapy is standard treatment for esophageal and gastroesophageal junction cancers. For gastric cancer, the need to include radiation therapy appears to depend on the quality of the surgery performed. Radiation therapy plays an uncertain role in the surgical management of pancreatic cancer, and the results of ongoing clinical trials are awaited...
May 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28589183/the-clinicopathologic-characteristics-and-prognostic-factors-of-gastroesophageal-junction-tumors-according-to-siewert-classification
#19
Bala Başak Öven Ustaalioğlu, Metin Tilki, Ali Sürmelioğlu, Ahmet Bilici, Can Gönen, Recep Ustaalioğlu, Özlem Balvan, Mehmet Aliustaoğlu
OBJECTIVE: The treatment of gastroesophageal junction tumors remains controversial due to confusion on whether they should be considered as primary esophageal or as gastric tumors. The incidence of these tumors with poor prognosis has increased, thus creating scientific interest on gastroesophageal cancers. Esophagogastric cancers are classified according to their location by Siewert, and the treatment of each type varies. We evaluated the prognostic factors and differences in clinicopathologic factors of patients with gastroesophageal junction tumor, who have been treated and followed-up in our clinics...
2017: Turk J Surg
https://www.readbyqxmd.com/read/28578142/impact-of-lymph-node-ratio-in-selecting-patients-with-resected-gastric-cancer-for-adjuvant-therapy
#20
Yuhree Kim, Malcolm H Squires, George A Poultsides, Ryan C Fields, Sharon M Weber, Konstantinos I Votanopoulos, David A Kooby, David J Worhunsky, Linda X Jin, William G Hawkins, Alexandra W Acher, Clifford S Cho, Neil Saunders, Edward A Levine, Carl R Schmidt, Shishir K Maithel, Timothy M Pawlik
BACKGROUND: The impact of adjuvant chemotherapy and chemo-radiation therapy in the treatment of resectable gastric cancer remains varied. We sought to define the clinical impact of lymph node ratio on the relative benefit of adjuvant chemotherapy or chemo-radiation therapy among patients having undergone curative-intent resection for gastric cancer. METHODS: Using the multi-institutional US Gastric Cancer Collaborative database, 719 patients with gastric adenocarcinoma who underwent curative-intent resection between 2000 and 2013 were identified...
August 2017: Surgery
keyword
keyword
110187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"